

Application No.: Not Yet Assigned
Page 2

IN THE CLAIMS:

Please cancel claims 1-23, 40 and 48-64.

Please amend claims 25, 27, 36, 38, 42, and 44 as follows:

A1
25. (Amended) The method of claim 24, wherein said AGL1/5-like gene product comprises a polypeptide sequence at least 50% identical to SEQ ID NO:4.

A2
27. (Amended) The method of claim 24, wherein said AGL1/5-like gene product comprises a polypeptide sequence at least 50% identical to SEQ ID NO:6.

A3
36. (Amended) The method of claim 30, wherein said AGL1/5-like gene product comprises a polypeptide sequence at least 50% identical to SEQ ID NO:4.

A4
38. (Amended) The method of claim 30, wherein said AGL1/5-like gene product comprises a polypeptide sequence at least 50% identical to SEQ ID NO:6.

A5
42. (Amended) The transgenic vascular plant of claim 41, wherein said AGL1/5-like gene product comprises a polypeptide sequence at least 50% identical to SEQ ID NO:4.

44. (Amended) The transgenic vascular plant of claim 41, wherein said AGL1/5-like gene product comprises a polypeptide sequence at least 50% identical to SEQ ID NO:6.

REMARKS

1. Status of the claims

With this Amendment, claims 1-23, 40 and 48-64 are canceled without prejudice to subsequent revival. Claims 25, 27, 36, 38, 42, and 44 are amended. Therefore, claims 24-39 and 41-47 are pending with entry of this Amendment.

A marked up copy of amended claims 25, 27, 36, 38, 42, and 44 are provided in Appendix A entitled "VERSION WITH MARKINGS TO SHOW